Phase 3 MARINE Trial Data To Be Presented In May At The National Lipid Association 2011 Annual Scientific Sessions

MYSTIC, Conn. and DUBLIN, April 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data from the MARINE trial, a pivotal Phase 3 study investigating AMR101 as a treatment for very high triglycerides (≥500 mg/dL), will be presented at the National Lipid Association (NLA) 2011 Annual Scientific Sessions at the Sheraton New York Hotel and Towers in New York City on May 19-22, 2011.

The MARINE trial results will be presented in an abstract titled "AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients With Very High Triglycerides Without Raising LDL-C: the MARINE Study" by Harold Bays, M.D., Medical Director, Louisville Metabolic and Atherosclerosis Research Center, and principal investigator of the study.  As reported in November 2010, the MARINE study met its primary endpoint of percent change in triglyceride (TG) levels from baseline to week 12, for both the 4 gram and 2 gram dose groups of AMR101. Additionally, the MARINE study demonstrated no statistically significant increase in LDL cholesterol and a safety profile similar to placebo.  

Two additional EPA-related abstracts will also be presented at the NLA annual meeting. The abstract titled "Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Low-Density Lipoprotein Cholesterol: A Critical Review" will be presented by Terry Jacobson, M.D. from Emory University, Atlanta, GA. The other abstract is titled "Comparative Lipid Antioxidant Effects of Omega-3 Fatty Acids in Combination with HMG-CoA Reductase Inhibitors" and will be presented by Preston Mason, Ph.D. from Elucida Research, Beverly, MA and Harvard Medical School. All three of the studies were sponsored by Amarin.

Following the presentation of MARINE results at the above forum in May, Amarin, together with clinical investigators from the MARINE study, plans to publish additional data from the MARINE trial, including data related to statistically significant reductions in several important lipid and inflammatory markers such as Apo B, Lp-PLA2, VLDL-C, LDL particle number, and total cholesterol.

1 2 Next › Last »